Harbour BioMed Expands Partnership with Spruce Biosciences to Advance SPR202 Development

Harbour BioMed Strengthens Collaborative Ties with Spruce Biosciences

Harbour BioMed, a biopharmaceutical company specializing in novel antibody therapeutics, announces a significant development in its strategic partnership with Spruce Biosciences, Inc. With the recent exercise of a warrant to acquire common stock, Harbour BioMed now holds approximately 3.8% of Spruce's total outstanding shares. This transaction represents a shift in the relationship between the two companies, evolving from a traditional licensor-licensee dynamic into a more integrated collaborative partnership. This transformation underscores Harbour BioMed's commitment to advancing innovative treatments in immunology and oncology, particularly through their joint efforts on SPR202, a monoclonal antibody targeting corticotropin-releasing hormone.

The collaboration between Harbour BioMed and Spruce is rooted in the aim of developing SPR202, which is poised to address a pressing need in the treatment of congenital adrenal hyperplasia. Dr. Jingsong Wang, Harbour BioMed’s CEO, points out that this partnership not only enhances the developmental capabilities for SPR202 but also demonstrates the company’s strategic intent to cultivate long-term relationships that foster growth and innovation within the biopharmaceutical landscape. As Harbour BioMed leverages its proprietary Harbour Mice® technology platform, which facilitates the production of fully human monoclonal antibodies, the collaboration is expected to yield therapeutic solutions that could significantly impact patient care.

In addition to its focus on SPR202, Harbour BioMed is dedicated to expanding its therapeutic pipeline through its advanced research and development (R&D) framework. The company utilizes cutting-edge technologies, such as HCAb-based immune cell engagers and immune cell antagonists, to develop treatments that address a range of immunological and inflammatory diseases. By harnessing these innovative approaches, Harbour BioMed is poised to lead in the biopharmaceutical sector, continuously improving and broadening its therapeutic offerings for patients worldwide.

Moreover, the agreement not only solidifies Harbour BioMed's stake in Spruce Biosciences but also highlights the importance of strategic collaborations in the biopharmaceutical industry. As companies increasingly seek to pool resources and expertise, such partnerships can accelerate the development of new therapies and enhance patient outcomes. This trend reflects a broader movement in the industry towards collaborative models that prioritize innovation and efficiency in drug development.